Carboplatin reinduction after taxane in patients with platinum-refractory epithelial ovarian cancer.

No abstract is available for this paper.

• Publication year

  1995

• Venue

  Journal of Clinical Oncology

• Publication date

  1995-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.1995.13.7.1584PMID 7602347
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Hexamethylmelamine as a single second-line agent in ovarian cancer: follow-up report and review of the literature.

  1997cited by this paper
• Dose-intense taxol: high response rate in patients with platinum-resistant recurrent ovarian cancer.

  1994cited by this paper
• Paclitaxel: a new antineoplastic agent for refractory ovarian cancer.

  1993cited by this paper
• Taxol and taxotere--current status and future prospects.

  1993cited by this paper
• Cross-resistance to diverse drugs is associated with primary cisplatin resistance in ovarian cancer cell lines.

  1993cited by this paper
• Hexamethylmelamine/altretamine as second-line therapy for epithelial ovarian carcinoma.

  1993cited by this paper
• Paclitaxel: a new antineoplastic agent for refractory ovarian cancer.

  1993cited by this paper
• Second‐line chemotherapy for recurrent carcinoma of the ovary

  1993cited by this paper
• Paclitaxel for platinum-refractory ovarian cancer: results from the first 1,000 patients registered to National Cancer Institute Treatment Referral Center 9103.

  1993cited by this paper
• Taxol dose intensification and its clinical implications.

  1993cited by this paper
• Mitomycin-C plus a 3-day continuous intravenous infusion of 5-fluorouracil: an inactive salvage regimen for platinum-resistant ovarian carcinoma.

  1993cited by this paper
• Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer.

  1992cited by this paper
• Role of carboplatin in ovarian cancer

  1992cited by this paper
• Responses to salvage chemotherapy in ovarian cancer: a critical need for precise definitions of the treated population.

  1992cited by this paper
• Phase II study and long-term follow-up of patients treated with taxol for advanced ovarian adenocarcinoma.

  1992cited by this paper
• Ifosfamide and mesna in previously treated advanced epithelial ovarian cancer: activity in platinum-resistant disease.

  1992cited by this paper
• Cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in advanced ovarian cancer: a randomized phase III study of the National Cancer Institute of Canada Clinical Trials Group.

  1992cited by this paper
• Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin.

  1991cited by this paper
• Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds.

  1990cited by this paper
• Taxol: A unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms

  1990cited by this paper
• Hexamethylmelamine as a single second‐line agent in ovarian cancer

  1990cited by this paper
• Randomized trial of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian carcinoma: a Gynecologic Oncology Group Study.

  1989cited by this paper
• Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms.

  1989cited by this paper
• Re-Treatment of Patients With Recurrent Epithelial Ovarian Cancer With Cisplatin-Based Chemotherapy

  1989cited by this paper
• Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and the design of phase II trials.

  1989cited by this paper
• Carboplatin dosage: prospective evaluation of a simple formula based on renal function.

  1989cited by this paper
• Cyclophosphamide-cisplatin versus cyclophosphamide-carboplatin in stage III-IV ovarian carcinoma: a comparison of equally myelosuppressive regimens.

  1989cited by this paper
• Phase II trial of mitomycin C plus 5-FU in the treatment of drug-refractory ovarian cancer.

  1988cited by this paper

• Rechallenge with platinum-based chemotherapy in patients with platinum-resistant ovarian carcinoma: A cohort study.

  2025cites this paper
• Cytoreductive surgery is feasible in patients with limited regional platinum-resistant recurrent ovarian cancer

  2023cites this paper
• INOVATYON/ ENGOT-ov5 study: Randomized phase III international study comparing trabectedin/pegylated liposomal doxorubicin (PLD) followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 months after last platinum line

  2023cites this paper
• Results of a Phase II Trial Testing the Resensitization With Trabectedin in Platinum-resistant Ovarian Cancer.

  2023cites this paper
• Investigation of cytotoxic and apoptotic effects of disodium pentaborate decahydrate on ovarian cancer cells and assessment of gene profiling

  2022cites this paper
• Targeting the Copper Transport System to Improve Treatment Efficacies of Platinum-Containing Drugs in Cancer Chemotherapy

  2021cites this paper
• Adavosertib with Chemotherapy in Patients with Primary Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer: An Open-Label, Four-Arm, Phase II Study

  2021cites this paper
• Successful Management of Platinum-resistant Ovarian Cancer by Weekly Nedaplatin Followed by Olaparib: Three Case Reports

  2020cites this paper
• Pegylated liposomal doxorubicin re-challenge in patients with ovarian cancer relapse: a multicenter retrospective study

  2019cites this paper
• Trabectedin for reversing platinum resistance and resensitization to platinum in patients with recurrent ovarian cancer.

  2019cites this paper
• Phase I/Ib study of olaparib and carboplatin in heavily pretreated recurrent high-grade serous ovarian cancer at low genetic risk

  2019cites this paper
• Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer

  2017cites this paper
• Cancer de l’ovaire : la rechute précoce

  2017cites this paper
• Moving beyond the platinum sensitive/resistant paradigm for patients with recurrent ovarian cancer.

  2016cites this paper
• The Next Steps in Improving the Outcomes of Advanced Ovarian Cancer

  2015cites this paper
• Nab-Paclitaxel in Recurrent Ovarian Cancer: An Institution Based Retrospective Study

  2015cites this paper
• Review of Cisplatin and Oxaliplatin in Current Immunogenic and Monoclonal Antibodies Perspective

  2014cites this paper
• Retreatment with bevacizumab in patients with gynecologic malignancy is associated with clinical response and does not increase morbidity

  2014cites this paper
• Emerging treatment strategies in recurrent platinum-sensitive ovarian cancer: focus on trabectedin.

  2014cites this paper
• Pegylated liposomal doxorubicin in the management of ovarian cancer

  2014cites this paper
• Review of Cisplatin and Oxaliplatin in Current Immunogenic and Monoclonal Antibody Treatments

  2014cites this paper
• Treatment options in recurrent ovarian cancer: latest evidence and clinical potential

  2014cites this paper
• Optimizing treatment of the partially platinum-sensitive ovarian cancer patient.

  2013cites this paper
• Exploratory study of carboplatin plus the copper-lowering agent trientine in patients with advanced malignancies

  2013cites this paper
• Systemic treatment for recurrent epithelial ovarian cancer

  2013cites this paper
• Clinical Outcome of Paclitaxel and Carboplatin as Second-Line Chemotherapy for Advanced Urothelial Carcinoma Resistant to First-Line Therapy with Gemcitabine and Cisplatin

  2013cites this paper
• Phase II study of ifosfamide and cisplatin for the treatment of recurrent ovarian cancer

  2013cites this paper
• Trabectedin as a new chemotherapy option in the treatment of relapsed platinum sensitive ovarian cancer.

  2012cites this paper
• Overcoming Platinum Resistance through the Use of a Copper-Lowering Agent

  2012cites this paper
• Oral Etoposide for the Treatment of Recurrent Ovarian Cancer

  2012cites this paper
• Chemotherapeutic management of recurrent ovarian cancer

  2012cites this paper
• Extending platinum-free interval in partially platinum-sensitive recurrent ovarian cancer by a non-platinum regimen: its possible clinical significance.

  2012cites this paper
• Trabectedin plus pegylated liposomal doxorubicin in the treatment of patients with partially platinum-sensitive ovarian cancer: current evidence and future perspectives.

  2012cites this paper
• Cáncer de ovario recurrente: Importancia del intervalo libre de platinos Recurrent ovarian cancer: Importance of the platinum-free interval

  2012cites this paper
• Ovarialkarzinom: alte Probleme und neue Lösungsansätze

  2011cites this paper
• Phase 1b‐2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum‐resistant or platinum‐refractory epithelial ovarian cancer

  2011cites this paper
• Phase II study of belotecan, a camptothecin analogue, in combination with carboplatin for the treatment of recurrent ovarian cancer

  2011cites this paper
• Phase II study of the combination carboplatin plus celecoxib in heavily pre-treated recurrent ovarian cancer patients

  2011cites this paper
• Recurrent Ovarian Cancer: When and How to Treat

  2011cites this paper
• Benefits of Enhancing the Platinum-Free Interval in the Treatment of Relapsed Ovarian Cancer: More Than Just a Hypothesis?

  2011cites this paper
• Feasibility of extension of platinum-free interval with weekly bolus topotecan and subsequent platinum retreatment outcomes in recurrent ovarian cancer

  2011cites this paper
• Carboplatin/gemcitabine alternating with carboplatin/pegylated liposomal doxorubicin and carboplatin/cyclophosphamide in platinum-refractory/resistant paclitaxel - pretreated ovarian carcinoma.

  2010cites this paper
• A double‐blind, randomized trial of pyridoxine versus placebo for the prevention of pegylated liposomal doxorubicin‐related hand‐foot syndrome in gynecologic oncology patients

  2010cites this paper
• Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6–12 months) subpopulation of OVA-301 phase III randomized trial

  2010cites this paper
• The Efficacy and Toxicity of Belotecan (CKD-602), A Camptothecin Analogue Topoisomerase I Inhibitor, in Patients with Recurrent or Refractory Epithelial Ovarian Cancer

  2010cites this paper
• Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free interval

  2010cites this paper
• The efficacy and toxicity of belotecan (CKD-602), a camptothericin analogue topoisomerase I inhibitor, in patients with recurrent or refractory epithelial ovarian cancer.

  2010cites this paper
• Pegylated liposomal doxorubicin combined with carboplatin: a rational treatment choice for advanced ovarian cancer.

  2010cites this paper
• Epithelial Ovarian Cancer: Role of Pegylated Liposomal Doxorubicin in Prolonging the Platinum-Free Interval and Cancer Antigen 125 Trends During Treatment

  2009cites this paper
• Phase II evaluation of nanoparticle albumin-bound paclitaxel in platinum-sensitive patients with recurrent ovarian, peritoneal, or fallopian tube cancer.

  2009cites this paper
• Phase II randomized study of trabectedin given as two different every 3 weeks dose schedules (1.5 mg/m2 24 h or 1.3 mg/m2 3 h) to patients with relapsed, platinum-sensitive, advanced ovarian cancer.

  2009cites this paper
• Weekly combination of topotecan and gemcitabine in early recurrent ovarian cancer patients: a French multicenter phase II study.

  2009cites this paper
• Gemcitabine and pegylated liposomal doxorubicin alternating with cisplatin plus cyclophosphamide in platinum refractory/resistant, paclitaxel-pretreated, ovarian carcinoma.

  2008cites this paper
• Phase II evaluation of CKD-602, a camptothecin analog, administered on a 5-day schedule to patients with platinum-sensitive or -resistant ovarian cancer.

  2008cites this paper
• Genetic classification of ovarian carcinoma based on microsatellite analysis: relationship to clinicopathological features and patient survival.

  2008cites this paper
• Weekly paclitaxel/5-fluorouracil followed by platinum retreatment for patients with recurrent ovarian cancer: a single institution experience.

  2008cites this paper
• ACTIVIDAD CITOTÓXICA DEL EXTRACTO ETANÓLICO DE Gnaphalium spicatum "KETO KETO " EN CULTIVOS DE LÍNEAS CELULARES TUMORALES HUMANAS

  2008cites this paper
• Leptomeningeal dissemination of ovarian carcinoma through a ventriculoperitoneal shunt.

  2008cites this paper
• Management of partially platinum-sensitive relapsed ovarian cancer

  2008cites this paper
• Prognostic factors associated with response in platinum retreatment of platinum-resistant ovarian cancer

  2007cites this paper
• Phase I and pharmacokinetic trial of AP5346, a DACH–platinum–polymer conjugate, administered weekly for three out of every 4 weeks to advanced solid tumor patients

  2007cites this paper
• Persistent mismatch repair deficiency following targeted correction of hMLH1

  2007cites this paper
• Treatment of recurrent ovarian cancer relapsing 6-12 months post platinum-based chemotherapy.

  2007cites this paper
• Update in the management of ovarian and cervical carcinoma

  2007cites this paper
• Aromatase inhibitors in ovarian cancer: is there a role?

  2007cites this paper
• Paclitaxel Carboplatin chemotherapy as a second‐line chemotherapy for advanced platinum resistant urothelial cancer in Japanese cases

  2007cites this paper
• Extending the Platinum-Free Interval with a Non-Platinum Therapy in Platinum-Sensitive Recurrent Ovarian Cancer

  2007cites this paper
• Validation de facteurs potentiels de chimiorésistance du cancer de l'ovaire par immunohistochimie

  2006cites this paper
• Traitement médical des rechutes (récidives) précoces

  2006cites this paper
• Extra‐ovarian Primary Peritoneal Carcinomas

  2006cites this paper
• Advances in Brief in Vitro and in Vivo Resistance to Cisplatin in Cells That Have Lost DNA

  2006cites this paper
• Management Strategies for Partially Platinum-Sensitive Ovarian Cancer

  2006cites this paper
• Rational use of cytotoxic chemotherapy for recurrent ovarian cancer.

  2006cites this paper
• LA INESTABILIDAD GENÓMICA EN CÁNCER

  2006cites this paper
• Update on the Treatment of Recurrent Ovarian Cancer

  2006cites this paper
• Management of recurrent epithelial ovarian carcinoma

  2005cites this paper
• Epithelial ovarian cancer: a review of current management.

  2005cites this paper
• [Advanced ovarian cancer: a need for redefining therapeutic objectives and strategy].

  2005cites this paper
• The use of topotecan for relapsed ovarian cancer in accordance with the National Institute for Clinical Excellence Guidance 2001: the Nottingham experience.

  2004cites this paper
• How Should We Manage Patients with “Platinum-Sensitive” Recurrent Ovarian Cancer?

  2004cites this paper
• Chapter 32 – Decision-Making in the Management of Recurrent Epithelial Ovarian Cancer

  2004cites this paper
• Telomere dynamics determine episodes of anticancer drug resistance in rat hepatoma cells

  2004cites this paper
• Telomere dynamics determine episodes of anticancer drug resistance in rat hepatoma cells

  2004cites this paper
• Role of Pegylated Liposomal Doxorubicin (PLD) in Epithelial Ovarian Cancer

  2004cites this paper
• The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.

  2004cites this paper
• Retrospective review: re-treatment of patients with ovarian cancer with carboplatin after platinum resistance

  2004cites this paper
• Recurrent Ovarian Cancer

  2004cites this paper
• Medical treatment of epithelial ovarian cancer

  2004cites this paper
• Topotecan and ifosfamide as salvage treatment in advanced ovarian cancer.

  2004cites this paper
• Platinum retreatment of platinum-resistant ovarian cancer after nonplatinum therapy.

  2003cites this paper
• Resistance to chemotherapy in advanced ovarian cancer: mechanisms and current strategies

  2003cites this paper
• The clinical importance and prognostic implications of microsatellite instability in sporadic cancer.

  2003cites this paper
• Salvage therapy for recurrent epithelial ovarian cancer.

  2003cites this paper
• Gemcitabine reverses cisplatin resistance: demonstration of activity in platinum- and multidrug-resistant ovarian and peritoneal carcinoma.

  2003cites this paper
• Current Therapies in Ovarian Cancer

  2003cites this paper
• Optimal sequencing in the treatment of recurrent ovarian cancer.

  2003cites this paper
• Platinum-Resistant and Refractory Ovarian Cancer

  2003cites this paper
• Chemotherapy of Ovarian Cancer

  2003cites this paper
• What are the clinical trial priorities of the future

  2003cites this paper
• CHAPTER 33 – The Long-Term Management of Ovarian Cancer

  2003cites this paper